{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:42:08Z","timestamp":1791639728307,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The activity of isavuconazole and other triazoles against non-fumigatus (non-AFM) Aspergillus causing invasive aspergillosis was evaluated. A total of 390 non-AFM isolates were collected (1\/patient) in 2017\u20132021 from 41 hospitals. Isolates were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry and\/or internal spacer region\/\u03b2-tubulin sequencing and tested by Clinical and Laboratory Standards Institute (CLSI) broth microdilution. CLSI epidemiological cutoff values were applied, where available. Isavuconazole showed activity against Aspergillus sections Flavi (n = 122; minimum inhibitory concentration [MIC]50\/90, 0.5\/1\u2005mg\/L), Terrei (n = 57; MIC50\/90, 0.5\/0.5\u2005mg\/L), Nidulantes (n = 34; MIC50\/90, 0.12\/0.25\u2005mg\/L), Versicolores (n = 7; MIC50, 1\u2005mg\/L), and Circumdati (n = 2; MIC range, 0.12\u20132\u2005mg\/L). Similar activity was displayed by other triazoles against those Aspergillus sections. Most of the isolates from Aspergillus sections Fumigati (n = 9), Nigri (n = 146), and Usti (n = 12) exhibited elevated MIC values to isavuconazole (MIC50\/90, 2\/\u2013, 2\/4, and 2\/8\u2005mg\/L), voriconazole (MIC50\/90, 2\/\u2013, 1\/2, and 4\/8\u2005mg\/L), itraconazole (MIC50\/90, 2\/\u2013, 2\/4, and 8\/&amp;gt;8\u2005mg\/L), and posaconazole (MIC50\/90, 0.5\/\u2013, 0.5\/1, and &amp;gt;8\/&amp;gt;8\u2005mg\/L), respectively. Isavuconazole was active (MIC values, \u22641\u2005mg\/L) against Aspergillus parasiticus, Aspergillus tamarii, Aspergillus nomius, Aspergillus nidulans, Aspergillus unguis, Aspergillus terreus, Aspergillus alabamensis, and Aspergillus hortai, while isavuconazole MIC values between 2 and 8\u2005mg\/L were observed against cryptic isolates from Aspergillus section Fumigati. Isavuconazole inhibited 96.1% of Aspergillus niger and 80.0% of Aspergillus tubingensis at \u22644\u2005mg\/L, the CLSI wild-type cutoff value for A niger. Voriconazole, itraconazole, and posaconazole showed similar activity to isavuconazole against most cryptic species. Isavuconazole exhibited potent in vitro activity against non-AFM; however, the activity of triazoles varies among and within cryptic species.<\/jats:p>","DOI":"10.1093\/ofid\/ofae532","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T12:16:58Z","timestamp":1730463418000},"source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of the Activity of Triazoles Against Non-<i>fumigatus Aspergillus<\/i> and Cryptic <i>Aspergillus<\/i> Species Causing Invasive Infections Tested in the SENTRY Program"],"prefix":"10.1093","volume":"11","author":[{"given":"Michael A","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories , North Liberty, Iowa ,","place":["USA"]},{"name":"University of Iowa , Iowa City, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G","family":"Carvalhaes","sequence":"additional","affiliation":[{"name":"JMI Laboratories , North Liberty, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Rhomberg","sequence":"additional","affiliation":[{"name":"JMI Laboratories , North Liberty, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Klauer","sequence":"additional","affiliation":[{"name":"JMI Laboratories , North Liberty, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories , North Liberty, Iowa ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"2024112610413503400_ofae532-B1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11046-014-9774-0","article-title":"Multi-resistant aspergillosis due to cryptic species","volume":"178","author":"Howard","year":"2014","journal-title":"Mycopathologia"},{"key":"2024112610413503400_ofae532-B2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/jof9040500","article-title":"Diagnosis and treatment of invasive aspergillosis caused by non-fumigatus Aspergillus spp","volume":"9","author":"Stemler","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2024112610413503400_ofae532-B3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11046-014-9775-z","article-title":"Antifungal susceptibility profile of cryptic species of Aspergillus","volume":"178","author":"Alastruey-Izquierdo","year":"2014","journal-title":"Mycopathologia"},{"key":"2024112610413503400_ofae532-B4","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.cmi.2016.05.013","article-title":"Previously unknown species of Aspergillus","volume":"22","author":"Gautier","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024112610413503400_ofae532-B5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11046-014-9811-z","article-title":"Treatment of infections by cryptic Aspergillus species","volume":"178","author":"Nedel","year":"2014","journal-title":"Mycopathologia"},{"key":"2024112610413503400_ofae532-B6","doi-asserted-by":"crossref","first-page":"ofy213","DOI":"10.1093\/ofid\/ofy213","article-title":"Emerging Aspergillus species almost exclusively associated with primary immunodeficiencies","volume":"5","author":"Seyedmousavi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2024112610413503400_ofae532-B7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.micpath.2018.01.047","article-title":"Predominance of non-fumigatus Aspergillus species among patients suspected to pulmonary aspergillosis in a tropical and subtropical region of the Middle East","volume":"116","author":"Zanganeh","year":"2018","journal-title":"Microb Pathog"},{"key":"2024112610413503400_ofae532-B8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3390\/jof8040411","article-title":"Unravelling the molecular identification and antifungal susceptibility profiles of Aspergillus spp. isolated from chronic pulmonary aspergillosis patients in Jakarta, Indonesia: the emergence of cryptic Species","volume":"8","author":"Rozaliyani","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2024112610413503400_ofae532-B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-023-00459-z","article-title":"Invasive aspergillosis and the impact of azole-resistance [manuscript published online ahead of print 18 March 2023]","author":"Bosetti","year":"2023","journal-title":"Curr Fungal Infect Rep"},{"key":"2024112610413503400_ofae532-B10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024112610413503400_ofae532-B11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2024112610413503400_ofae532-B12","doi-asserted-by":"crossref","first-page":"S436","DOI":"10.1093\/infdis\/jix210","article-title":"Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Chowdhary","year":"2017","journal-title":"J Infect Dis"},{"key":"2024112610413503400_ofae532-B13","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/myc.13267","article-title":"Isavuconazole nonwildtype Aspergillus fumigatus isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles","volume":"64","author":"Castanheira","year":"2021","journal-title":"Mycoses"},{"key":"2024112610413503400_ofae532-B14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-012-9551-x","article-title":"Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme","volume":"174","author":"Pfaller","year":"2012","journal-title":"Mycopathologia"},{"key":"2024112610413503400_ofae532-B15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","article-title":"Isavuconazole, micafungin, and 8 comparator antifungal agents\u2019 susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024112610413503400_ofae532-B16","doi-asserted-by":"crossref","first-page":"e01230-18","DOI":"10.1128\/AAC.01230-18","article-title":"In vitro activity of isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610413503400_ofae532-B17","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"2024112610413503400_ofae532-B18","volume-title":"Epidemiological cutoff values for antifungal susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2022"},{"key":"2024112610413503400_ofae532-B19","volume-title":"Performance standards for antifungal susceptibility testing of filamentous fungi","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2022"},{"key":"2024112610413503400_ofae532-B20","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112610413503400_ofae532-B21","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2024112610413503400_ofae532-B22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/jof4030103","article-title":"Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates","volume":"4","author":"Buil","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"2024112610413503400_ofae532-B23","volume-title":"Epidemiological cutoff values for antifungal susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"2024112610413503400_ofae532-B24","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/myc.13348","article-title":"Invasive aspergillosis due to Aspergillus cryptic species: a prospective multicentre study","volume":"64","author":"Imbert","year":"2021","journal-title":"Mycoses"},{"key":"2024112610413503400_ofae532-B25","doi-asserted-by":"crossref","first-page":"115007","DOI":"10.1016\/j.diagmicrobio.2020.115007","article-title":"In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY antifungal surveillance program, 2017\u20132018","volume":"97","author":"Messer","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024112610413503400_ofae532-B26","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/jof9060608","article-title":"In vitro activity of isavuconazole and other mould-active azoles against Aspergillus fumigatus with and without CYP51 alterations","volume":"9","author":"Pfaller","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2024112610413503400_ofae532-B27","author":"Kleiboeker","year":"2018"},{"key":"2024112610413503400_ofae532-B28","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024112610413503400_ofae532-B29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3109\/13693786.2012.684154","article-title":"Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection","volume":"50","author":"Hadrich","year":"2012","journal-title":"Med Mycol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae532\/60750898\/ofae532.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/11\/ofae532\/60750898\/ofae532.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T10:41:53Z","timestamp":1732617713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae532\/7862666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae532","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,30]]},"article-number":"ofae532"}}